Antibody Technologies

Specific antibodies are invaluable both in diagnostics as well as treatment. The Cell-free Protein Synthesis Unit uses eukaryotic cell extracts as a new strategy for the efficient and reliable synthesis and selection of antibodies (e.g. IgG) and antibody fragments (e.g. scFv). In contrast to conventional methods for generating antibodies, this saves a great deal of time and money. Open eukaryotic in-vitro translation systems additionally offer plenty of leeway for modifications that improve the quality and expand the properties of the proteins in question. The cell-free synthesis of antibody-toxin conjugates, for example, which cannot be synthesized in vivo, opens up potential for pharmacological applications. Proteinogenic toxins can – without requiring living cells – be produced using linear DNA templates in parallel and flexibly scalable cell-free reactions. Neither cloning nor cell cultivation is required for the direct production of proteinogenic toxins. This eliminates work in safety level 2+ laboratories and the inefficient purification of the toxins from genetically modified microorganisms. By optimizing the biological processes in defined reaction environments, the conditions for synthesis can be individually modified to meet the requirements for the respective protein. This also allows for parallel expression screening of different protein-coded sequences, as well as the testing of suitable reaction parameters for a particular protein.